Zynerba Pharmaceuticals (NASDAQ: ZYNE) announced 5/29/2019, initiation of phase 2 INSIPRE trial for its lead product ZYGEL. ZYGEL is a trans-dermal CBD gel. The ZYGEL trial is looking at efficacy of patients with defects of chromosome 22 ( 22q11.2 ).
22q11.2 deletion is an inherited pediatric condition with wide range of symptoms. Symptoms include emotional and mild behavioral issues to physical, psychological, and even heart and immune system problems.
According to Zynerba, top-line data results for INSPIRE are expected next year. Although I like ZYNE’s long term prospects, this pattern tends to repeat itself quite frequently, especially with volatility in broader markets during this time. Furthermore, with phase 2 just initiated it will likely be a couple months before the next data read, leaving more reason for investors and traders to go elsewhere. Not only do charts indicate further downside but I believe this will cause more sellers than buyers in coming months.
- Currently sitting at .382 retracement.
- Pullback to .50 retracement is ~$9.54 bringing puts in the money
- Looking for test of .5 retracement by end of month
- Technical’s indicate potential AB=BC harmonic retracement/ pullback.
I/ We own puts in ZYNE. This is not recommendation to buy or sell. Please be sure to do your DD before investing.
MS Money Move and its Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.
The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.